Treatment of Intermediate-stage Hepatocellular Carcinoma
NCT ID: NCT03274427
Last Updated: 2017-09-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
300 participants
INTERVENTIONAL
2017-07-18
2021-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
One-drug Regimes
Basic drugs therapy of HCC by TACE.
Basic drugs therapy of HCC by TACE
Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
Two-Drug Regimens
Basic drugs therapy of HCC by TACE; Arginine hydrochloride
Basic drugs therapy of HCC by TACE
Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
Arginine hydrochloride
Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
Three-Drug Regimens
Basic drugs therapy of HCC by TACE; Arginine hydrochloride;Trimetazidine hydrochloride
Basic drugs therapy of HCC by TACE
Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
Arginine hydrochloride
Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
Trimetazidine hydrochloride
Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Basic drugs therapy of HCC by TACE
Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
Arginine hydrochloride
Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
Trimetazidine hydrochloride
Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2\. The diagnosis of HCC: in accordance with "diagnostic and treating standards on primary liver cancer" (2011 Edition) or histological/cytological diagnosis of primary liver cancer
* 3\. Un-resectable HCC who are eligible for TACE: patients with developing primary liver cancer of Barcelona stage(BCLC) B; multiple nodules (less than 5, the total diameter of less than 20 cm), no invasion, no symptoms; refusing open surgical treatment and volunteering for the treatment
* 4\. There are CT or MRI measurable lesions
* 5\. No major vascular invasion or extra hepatic metastasis
* 6\. Child-Pugh liver function class A/B(score: ≤7)
* 7\. Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale in one week before admission
* 8\. Estimated survival time \> 3 months
* 9\. HBV DNA\<2000 IU/ml（10\^4 copies/ml); or HBV DNA≥2000 IU/ml and are accepting effective antiviral therapy
* 10\. The major organ function is normal. that is meeting the following standards:
1. Blood routine examination: (No blood transfusion, no G-CSF and no medication were corrected within 14 days before screening)
a.HB≥80g/L； b.ANC≥1.5×109/L；c.PLT≥50×109/L；
2. Biochemical examination: (ALB was not transfused within 14 days before screening) a.ALB ≥29 g/L； b.ALT和AST\<5ULN；c.TBIL ≤3ULN；d.creatinine ≤1.5ULN( albumin and bilirubin, two indicators of Child-Pugh liver function class, can only have one for 2 points)
* 11\. For women of childbearing age, the results of serum/urine pregnancy tests must be negative within 7 days before initiation of treatment. All men and women who participate in the study have to take reliable contraceptive measures within the trial and eight weeks after the trial is completed
* 12\. volunteers must signed informed consent
Exclusion Criteria
* 2\. Vascular invasion, including portal vein tumor thrombus
* 3\. Extra hepatic metastasis
* 4\. Decompensated Cirrhosis: Child-Pugh liver function class B/C(score: \>8); jaundice; hepatic encephalopathy; refractory ascites; hepatorenal syndrome
* 5\. With a history of alimentary tract hemorrhage or a definite tendency of gastrointestinal bleeding, such as varices of fundus of stomach and esophagus with bleeding risk; local active ulcer lesions; fecal occult blood ≥（++）
* 6\. Contraindication of embolization: patients with severe hepatic flow or portosystemic shunt; the lesion was too large, and the majority of two lobe were occupied by the lesions
* 7\. Patients whose target lesion has been treated locally: resection of hepatic carcinoma; radio frequency ablation; TACE; local treatment was taken within 4 weeks; patients who have previously been given radiotherapy, chemotherapy, or targeted drugs
* 8\. Patients with hepatobiliary cell carcinoma, mixed cell carcinoma or lamellar cell carcinoma; in the past (within 5 years) or at the same time suffering from other untreated malignant tumors; excluding cured basal cell carcinoma and carcinoma in situs of cervix
* 9\. Patients who are undergoing liver transplantation or have a history of organ transplantation(excluding the patient who has undergone liver transplantation before)
* 10\. Patients with an allergic history of arginine hydrochloride and trimetazidine hydrochloride
* 11\. The blood pressure can not be reduced to the normal range by the antihypertensive drug treatment in patients with hypertension(systolic pressure\>140 mmHg, diastolic pressure\>90 mmHg)
* 12\. Patients with myocardial ischemia or myocardial infarction over grade II or a poorly controlled arrhythmia (including QTc interval: men ≥ 450 ms; women ≥ 470 ms)
* 13\. Cardiac functional insufficiency of grade III to IV according to NYHA standard; echocardiography: LVEF\<50%
* 14\. Many factors that influence oral medication, such as unable to swallow; chronic diarrhea; intestinal obstruction; the situations which significantly affect the use and absorption of drugs
* 15\. Abdominal fistula, gastrointestinal perforation, or abdominal abscess occurred within 28 days before participating the study
* 16\. Dysfunction of blood coagulation(INR\>2.0 or PT\> 16s，APTT \> 43s、TT \> 21s，Fbg \< 2g/L), having a tendency to bleed or undergoing thrombolysis or anticoagulant therapy; ascites with clinical symptoms, that is requiring therapeutic abdominal paracentesis or drainage or Child-Pugh score ≥2
* 17\. Objective evidence of pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug associated pneumonia, and severe lung function impairment in the past and at present
* 18\. Urine routine showed that urine protein ≥++ or the urine protein in 24 hours\>1.0 g
* 19\. Patients who have been treated with potent CYP3A4 inhibitors (ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, telithromycin, troleandomycin, erythromycin, cimetidine and so on) within 28 days before participating the study, or potent CYP3A4 inducers (dexamethasone, phenytoin, rifampin, rifabutin, carbamazepine, phenobarbitone and so on) within 12 days before participating the study
* 20\. Pregnant or lactating women; fertile patients who are unwilling or unable to adopt effective contraceptives
* 21\. Patients with mental sickness or the history of psychotropic drug abuse
* 22\. Patients with severe infection (unable to control the infection effectively)
* 23\. The treatment history affecting this program or its efficacy, such as stem cell transplantation, immune regulation (including PD-1 and other test regimens) recently (within half a year)
* 24\. The researchers believe that any other factors unsuitable for entering into the study.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Xinjiang Medical University
OTHER
Luoyang Central Hospital
OTHER
Nanyang Central Hospital
OTHER
Anyang Tumor Hospital
OTHER
Shenma Medical Group General Hospital
OTHER
First People's Hospital of Shangqiu
OTHER
Jiaozuo third people's hospital
UNKNOWN
The First Affiliated Hospital of Zhengzhou University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zujiang YU
The director of infectious diseases department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zujiang Yu
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Zhengzhou University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HETCT-002
Identifier Type: -
Identifier Source: org_study_id